Initial tests have shown that proteins modified by GPT-4b micro are over 50 times more effective at stimulating stem cell production compared to their natural counterparts.

Retro Biosciences is researching Yamanaka factors for potential therapies, aiming to extend healthy human lifespan by 10 years through anti-aging therapeutics.

The company's mission is to target the mechanisms of aging, leveraging the capabilities of AI to advance stem cell production through protein re-engineering.

Developed in collaboration with Retro Biosciences, which is backed by a substantial $180 million investment from OpenAI CEO Sam Altman, this model focuses on protein engineering.

This initiative underscores a growing gap between AI advancements in science and the current healthcare system, which remains primarily disease-focused.

OpenAI has made a significant move into longevity science with the launch of GPT-4b micro, a specialized AI model aimed at enhancing human lifespan.

GPT-4b micro has been trained on extensive biological data, allowing it to predict protein structures and interactions with greater accuracy than traditional methods.

The GPT-4b micro model is specifically designed to improve the effectiveness of Yamanaka factors, proteins that can convert adult cells into stem cells.

AI commentator David Shapiro has highlighted the revolutionary potential of this AI model in medicine, suggesting it could outperform human experts in the future.

OpenAI plans to make the research findings available for peer review in the future, although the project is still in its early phases.

The results of this groundbreaking research are expected to be published soon, generating excitement within the longevity science community.

AI assistance is crucial in this field, as human scientists currently face slow progress, with less than 1% of treated cells achieving full rejuvenation.